United States Biotechnology & Medical Research

Atossa Therapeutics Inc (ATOS)

Track

Atossa Therapeutics Inc. has recorded no insider trading activity within the last three months. The most recent transaction occurred on May 21, 2025, when the President and CEO executed a purchase of shares. Prior to this, there were additional buy transactions recorded in early 2025, with no reported sales by insiders during that period.
Ticker: ATOS Exchange: NAS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Atossa Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Buy 21 May 2025
Value US$1,994,577.53 | Price 66.68 | Shares 97,632 (-6.6%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-05-22 2025-05-21 B Purchase
1.3
QUAY STEVEN C

President & CEO

Executive Director
97,632 -6.6%
66.68
US$1,994,578 		97,632 -6.6% 66.68 US$1,994,578
2025-03-28 2025-03-26 B Purchase
3.1
Remmel H. Lawrence
Non-Executive Director
69,581 +45.9%
97.24
US$141,684 		69,581 +45.9% 97.24 US$141,684
2024-04-11 2024-04-10 B Purchase
0.6
Finn Jonathan
Non-Executive Director
92,101 +2.9%
456.15
US$4,028,165 		92,101 +2.9% 456.15 US$4,028,165
2023-11-17 2023-11-15 S Sale
1.5
WEAVER GREGORY L

Former EVP, CFO, & Director

Executive Director
50,000 -99.9%
0.65
US$32,500 		50,000 -99.9% 0.65 US$32,500
2023-06-20 2023-06-20 B Purchase
1.5
WEAVER GREGORY L

EVP & CFO

Executive Director
50,000 +90909.1%
0.97
US$48,500 		50,000 +90909.1% 0.97 US$48,500
2017-11-16 2017-11-15 B Purchase
2.5
Guse Kyle

CFO, Gen Counsel and Secretary
1,400 +16.3%
0.34
US$471 		1,400 +16.3% 0.34 US$471
2017-11-16 2017-11-15 B Purchase Guse Kyle

CFO, Gen Counsel and Secretary
8,600 +inf%
0.34
US$2,898 		8,600 +inf% 0.34 US$2,898
2017-04-18 2017-04-17 B Purchase Remmel H. Lawrence
2,500 +399.4%
0.63
US$1,580 		2,500 +399.4% 0.63 US$1,580
2016-04-04 2016-04-01 B Purchase Remmel H. Lawrence Non-Executive Director
1,500 +16.0%
0.33
US$495 		1,500 +16.0% 0.33 US$495
2016-03-10 2016-03-09 B Purchase Chen Shu-Chih Non-Executive Director Large shareholder
15,000 +0.3%
0.37
US$5,550 		15,000 +0.3% 0.37 US$5,550
2016-03-10 2016-03-09 B Purchase QUAY STEVEN C

President & CEO

Executive Director Large shareholder
15,000 +0.3%
0.37
US$5,550 		15,000 +0.3% 0.37 US$5,550
2016-02-17 2016-02-16 B Purchase Chen Shu-Chih Non-Executive Director Large shareholder
15,000 +0.3%
0.53
US$7,950 		15,000 +0.3% 0.53 US$7,950
2016-02-17 2016-02-16 B Purchase QUAY STEVEN C

President & CEO

Executive Director Large shareholder
15,000 +0.3%
0.53
US$7,950 		15,000 +0.3% 0.53 US$7,950
2016-01-21 2016-01-19 B Purchase
3.3
Chen Shu-Chih
Non-Executive Director Large shareholder
50,000 +1.2%
0.20
US$10,000 		50,000 +1.2% 0.20 US$10,000
2016-01-21 2016-01-19 B Purchase QUAY STEVEN C

President & CEO

Executive Director Large shareholder
50,000 +1.1%
0.20
US$10,000 		50,000 +1.1% 0.20 US$10,000
2015-06-15 2015-06-12 B Purchase Remmel H. Lawrence Non-Executive Director
5,400 +135.0%
1.30
US$7,020 		5,400 +135.0% 1.30 US$7,020
2013-06-27 2013-05-15 B Purchase CROSS ALEXANDER D Non-Executive Director
500 +0.6%
5.49
US$2,745 		500 +0.6% 5.49 US$2,745
2013-01-09 2013-01-08 B Purchase Remmel H. Lawrence Non-Executive Director
2,000 +inf%
4.05
US$8,100 		2,000 +inf% 4.05 US$8,100
2013-01-09 2013-01-08 B Purchase
3.3
Remmel H. Lawrence
Non-Executive Director
1,600 +400.0%
4.20
US$6,720 		1,600 +400.0% 4.20 US$6,720
2013-01-09 2013-01-08 B Purchase
3.3
Remmel H. Lawrence
Non-Executive Director
400 +inf%
4.10
US$1,640 		400 +inf% 4.10 US$1,640
Explore more

More insider trading research around Atossa Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America